혈액종양내과김정한 교수 사진

김정한

전문센터 : 항암센터 홈페이지

진료과 : 혈액종양내과 홈페이지

전문진료분야 : 폐암, 유방암, 위암, 대장암, 부인암, 두경부암, 악성림프종, 혈액암, 각종 빈혈, 혈액응고장애, 종양면역치료

전화 : 02-829-5113

이메일 : harricil@hallym.or.kr


(주간) 진료시간표 (2021-03-01 ~ 2021-03-06)

* 전화예약 : 1577-5587

전화 전화예약 ( 1577-5587)
의료진 진료시간표
진료시간
오전    센터진료      
오후    센터진료      

학 력

내용 숨기기
한림대학교 의과대학 졸업(95)
한림대학교 대학원 의학석사(99)
[논문: 위의 전암병변에서 H. Pylori와 telomerase 활성과의 관계]
성균관대학교 대학원 의학박사(06)
[논문: 전이성 신장암에서 수지상 세포를 이용한 면역치료의 효과]
2010, 미국 프레드허치슨 암연구소

경 력

내용 숨기기
한림대 한강성심병원 내과 전공의 수료 (2000)
삼성서울병원 혈액종양내과 전임의
한림대학교 의과대학 교수 (현재)
한림대학교강남성심병원 혈액종양내과 분과장 (현재)
한림대학교강남성심병원 항암센터 센터장 (현재)

가입학회 및 활동

내용 숨기기
대한내과학회
대한암학회
대한혈액학회
대한임상암학회
대한조혈모세포이식학회

수상경력

내용 숨기기
세계 3대 인명사전 등재

국제학회지 발표논문

내용 숨기기
1. Kim JH, Lee SH, Park J, Kim HY, Lee SI, Nam E, Park JO, Kim K, Jung CW, Im YH, Kang WK, Lee MH, Park K. Extrapulmonary small-cell carcinoma: a single-institution experience. Jpn J Clin Oncol 34:250-254, 2004.

2. Kim JH, Lee SH, Park J, Kim HY, Lee SI, Park JO, Kim K, Kim WS, Jung CW, Park YS, Im YH, Kang WK, Lee MH, Park K, Han JH, Ko YH. Primary pulmonary non-Hodgkin’s lymphoma. Jpn J Clin Oncol 34:510-514, 2004.

3. Lee SH, Kang WK, Park J, Kim HY, Kim JH, Lee SI, Park JO, Kim K, Jung CW, Park YS, Im YH, Lee MH, Park K. Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable gastric carcinoma. Br J Cancer 91:18-22, 2004.

4. Park J, Park BB, Kim JY, Lee SH, Lee SI, Kim HY, Kim JH, Park JO, Kim K, Jung CW, Park YS, Im YH, Kang WK, Lee MH, Park K. Gefitinib (ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small cell lung cancer. Clin Cancer Res 10:4383-4388, 2004.

5. Kim JH, Jung CW, Cho YH, Lee J, Lee SH, Kim HY, Park J, Park JO, Kim K, Kim WS, Park YS, Im YH, Kang WK, Park K. Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma. Oncol Report 13:859-864, 2005.

6. Oh SY, Ryoo BY, Kim WS, Kim K, Lee J, Kim HJ, Kwon JM, Lee HR, Ko YH, Oh SJ, Park KW, Kim HJ, Kwon HC, Nam E, Kim JH, Park YH, Lee SS, Kim HY, Park K. Nodal marginal zone B-cell lymphoma: analysis of 36 cases. Clinical presentation and treatment outcomes of nodal marginal zone B-cell lymphoma. Ann Hematol 85:781-786, 2006.

7. Lee J, Suh C, Park YH, Ko YH, Bang SM, Lee JH, Lee DH, Huh JR, Oh SY, Kwon HC, Kim HJ, Lee SI, Kim JH, Park J, Oh SJ, Kim K, Jung CW, Park K, Kim WS. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol 24:612-618, 2006.

8. Kim JH, Lee DH, Shin HC, Kwon JH, Jung JY, Kim HJ, Song HH, Lee KS, Zang DY, Ahn JS, Park YI, Lee JA. A phase study with gemcitabine and split-dose cisplatin in patients with non-small cell lung cancer. Lung Cancer 54:57-62, 2006.

9. Park BB, Ryoo BY, Lee JH, Kwon HC, Yang SH, Kang HJ, Oh SY, Ko YH, Huh JR, Lee SS, Nam E, Park KW, Kim JH, Kang JH, Bang SM, Park S, Kim K, Park K, Suh C, Kim WS. Clinical features and treatment outcomes of angioimmunoblastic T-cell lymphoma. Leuk Lymphoma 48:716-722, 2007.

10. Oh SY, Ryoo BY, Kim WS, Park YH, Kim K, Kim HJ, Kwon JM, Lee J, Ko YH, Ahn YC, Oh SJ, Lee SI, Kim HJ, Kwon HC, Bang SM, Kim JH, Park J, Lee SS, Kim HY, Park K. Nongastric marginal zone B-cell lymphoma: analysis of 247 cases. Am J Hematol 82:446-452, 2007.

11. Oh SY, Kwon HC, Kim WS, Hwang IG, Park YH, Kim K, Ko YH, Ryoo BY, Kang HJ, Nam E, Lee JH, Kim JH, Kim HJ. Intestinal marginal zone B-cell lymphoma of MALT type: clinical manifestation and outcome of rare disease. Eur J Haematol 79:287-291, 2007.

12. Park BB, Kim JG, Sohn SK, Kang HJ, Kang JH, Lee SS, HS Eom, Kwon HC, Oh SY, Shin HJ, Suh C, Kim JH, Kim HY, Kim K, Ryoo BY, Kim WS. Consideration of aggressive therapeutic strategies for primary testicular lymphoma. Am J Hematol 82:840-845, 2007.

13. Oh SY, Kwon HC, Kim WS, Park YH, Kim K, Kim HJ, Kwon JM, Lee J, Ko YH, Ahn YC, Oh SJ, Lee SI, Bang SM, Kim JH, Park J, Ryoo BY, Lee SS, Kim HY, Park K, Kim HJ. Nongastric marginal zone B-cell lymphoma: A prognostic model from a retrospective multicenter study. Cancer Lett 258: 90-97, 2007

14. Kim JH, Lee Y, Bae YS, Kim WS, Kim K, Im HY, Kang WK, Park K, Choi HY, Lee HM, Baek SY, Lee H, Doh H, Kim BM, Kim CY, Jeon CJ, Jung CW. Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma. Clin Immunol 2007;125:257-267.

15. Kim JH, Kim HS, Sung CW, Kim KJ, Kim CH, Lee KY. Docetaxel, gemcitabine, and cisplatin administered for non-small cell lung cancer during the first and second trimester of an unrecognized pregnancy. Lung Cancer 59:270-273, 2008

16. Jang HJ, Kim JH, Song HH, Woo KH, Kim M, Kae SH, Lee J, Cho JW, Kang JH, Lee SI, Gong SJ, Lee JA, Zang DY. Clinical Outcomes of Patients with Liver Cirrhosis Who Underwent Curative Surgery for Gastric Cancer: A Retrospective Multi-center Study. Dig Dis Sci 53:399-404, 2008.

17. Zang DY, Yang DH, Lee HW, Hwang SW, Song HH, Jung JY, Kwon JH, Kim HJ, Kim JH, Park SR, Kim MJ, Jang KM, Park CK, Kim JH, Lee BH. Phase I/II trial with docetaxel and S-1 for patients with advanced or recurrent gastric cancer with consideration to age. Cancer Chemother Pharmacol 63:509-516, 2009.

18. Kim JH, Kin HS et al. Bilateral subdural hematoma as a possible adverse events of gefitinib in a patient with non-small cell lung cancer. Lung Cancer, 64;121-3, 2009.

19. Jung JY, Kwon JH, Kim JH, Song HH, Kim I, Lee KS, Kim HJ, Zang DY, Ahn JS, Lee JA, Park YI. Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer. Oncol Rep 21:523-529, 2009.

20. Zang DY, Lee BH, Park HC, Song HH, Kim HJ, Jung JY, Kim JH, Kim HY, Kwon JH, Hwang SW, Park SR, Park CH, Kim KO, Kim MJ, Jang KM. Phase II study with oxaliplatin and S-1 for patients with metastatic colorectal cancer. Ann Oncol 20;892-896, 2009.

21. Zang DY, Yang DH, Kim MJ, Jang KM, Hwang SW, Yoo KS, Han T, Kim HY, Kim HJ, Kwon JH, Song HH, Park S, Jung JY, Kim HS, Kim JH. Dose-finding study of docetaxel, oxaliplatin, and S-1 for patients with advanced gastric cancer. Cancer Chemother Pharmacol. 64:877-83, 2009.

22. Kim JH, Kim HS, Kwon JH, Park S, Kim HY, Jung JY, Kim HJ, Song HH, Lee GW, Lee SI, Gong SJ, Lee JA, Kim KJ, Zang DY. Systemic chemotherapy after cranial irradiation in patients with brain metastases from non-small cell lung cancer: a retrospective study. Lung Cancer
63;405-409, 2009.

23. Kim HS, Lee GW, Kim JH, Kim HY, Kwon JH, Song HH, Kim HJ, Jung JY, Jang G, Choi DR, Park SM, Shin TR, Lee HS, Zang DY. A phase II study of pemetrexed and carboplatin as a salvage therapy for platinum-pretreated patients with non-small cell lung cancer. Lung Cancer. 70:71-6, 2010.

24. Kwon JH, Kim JH, Lee JA, Shin HC, Kim HJ, Song HH, Jung JY, Kim HY, Choi DR, Kim HS, Park YI, Zang DY. Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 66:889-97, 2010.

25. Kim JH, Kim M, Sung CW, Kim HS, Jang HJ, Shin YC, Jung JY. High-dose fentanyl patch for cancer pain of a patient with cholangiocarcinoma. Korean J Intern Med. 25:337-40, 2010.

26. Kim HS, Park YH, Lee J, Ahn JS, Kim J, Shim YM, Kim JH, Park K, Han J, Ahn MJ. Clinical impact of phosphorylated signal transducer and activator of transcription 3, epidermal growth factor receptor, p53, and vascular endothelial growth factor receptor 1 expression in resected adenocarcinoma of lung by using tissue microarray. Cancer 116:676-85, 2010.

27. Kim JH, Kim HS, Choi DR, Jang G, Kwon JH, Kim HY, Jung JY, Kim HJ, Song HH, Shin YH, Jung SY, Kim BC, Zang DY. A phase II study of mitomycin-C and S-1 as third-line chemotherapy in patients with advanced colorectal cancer. Oncol Lett. 2:1253-1256, 2011

28. Kim HJ, Moh IH, Yoo H, Son S, Jung DH, Lee HG, Han DH, Park JH, Kim HS, Kim JH. Ethylenediaminetetraacetic acid-dependent pseudothrombocytopenia associated with neuroendocrine carcinoma: A case report. Oncol Lett. 4:86-88, 2012.

29. Kim HS, Kim JH, Kim HJ, Jang HJ, Kim JB, Kim JW, Jung SY, Kim BC, Yang DH, Park S, Kim KJ, Lee SI, Zang DY. Oxaliplatin, 5-fluorouracil and leucovorin (modified FOLFOX-6) as first-line chemotherapy for advanced gastric cancer patients with poor performance status. Oncol Lett. 3:425-428, 2012.

30. Kim JH, Kim HS, Han AR, Moh IH, Chung DC, Choi DR, Jang HJ, Kim JB, Yang DH, Lee SI, Zang DY. Irinotecan, leucovorin and 5-fluorouracil (modified FOLFIRI) as salvage chemotherapy for frail or elderly patients with advanced gastric cancer. Oncol Lett. 4:751-754, 2012.

31. Kwon JH, Oh SY, Chisholm G, Lee JA, Lee JJ, Park KW, Nam SH, Song HH, Lee K, Zang DY, Kim HY, Choi DR, Kim HJ, Kim JH, Jung JY, Jang G, Kim HS, Won JY, Bruera E. Predictors of high score patient-reported barriers to controlling cancer pain: a preliminary report. Support Care Cancer 21:1175-1183, 2013.

32. Kim HS, Kim JH, Kim B, Choi HC, Kwon JH, Choi DR. Phase II study of weekly carboplatin and irinotecan as first-line chemotherapy for patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol 71:1591-1597, 2013

33. Song H, Han B, Park CK, Kim JH, Jeon JY, Kim IG, Kim HJ, Jung JY, Kim JH, Kwon JH, Jang G, Kim HY, Kim HS, Choi DR, Zang DY. Phase II trial of gemcitabine and S-1 for patients with advanced pancreatic cancer. Cancer Chemother Pharmacol. 2013

34. Jang G, Song HH, Park KU, Kim HS, Choi DR, Kwon JH, Kim HY, Han B, Kim JH, Jung JY, Kim HJ, Zang DY. A Phase II Study to Evaluate the Efficacy of Ramosetron, Aprepitant, and Dexamethasone in Preventing Cisplatin-Induced Nausea and Vomiting in Chemotherapy-Naïve Cancer Patients. Cancer Res Treat 45(3):172-7, 2013

35. Jang GS, Kim MJ, Ha HI, Kim JH, Kim HS, Ju SB, Zang DY. Comparison of RECIST version 1.0 and 1.1 in assessment of tumor response by computed tomography in advanced gastric cancer. Chin J Cancer Res 25(6):689-94, 2013

36. Jang HJ, Kim BC, Kim HS, Kim JH, Song HH, Kim JB, Park JJ, Yoon SN, Woo JY, Zang DY. Comparison of RECIST 1.0 and RECIST 1.1 on Computed Tomography in Patients with Metastatic Colorectal Cancer. Oncology 25;86(2):117-121, 2014.

37. Kim HS, Kim JH, Yang I. Tumor response assessment by measuring the single largest lesion per organ in patients with advanced non-small cell lung cancer. Lung Cancer, 85: 385-389, 2014.

38. Kim HS, Kim JH. Ideal number of target lesions per organ to measure in metastatic colorectal cancer. Oncol Lett, 2014;8:1896-1900.
39. Kim HS, Kim JW, Kim JH, Choi DR, Kim M-J, Han AR, et al. The single-lesion measurement for assessing tumor response in patients advanced gastric cancer. Oncology. 2015;88:69-75.

40. Kang JH, Oh SY, Song SY, Lee HY, Kim JH, Lee KE, Lee HR, Hwang IG, Park SH, Kim WS, Park YS, Park K. The efficacy of low-dose transdermal fentanyl in opioid-naïve cancer patients with moderate-to-severe pain. Korean J Intern Med. 2015;30(1):88-95.

41. Kim BC, Jung SW, Kim JB, Han AR, Jang SI, Park SH, Lee MS, Yoon JH, Baik GH, Jang HJ, Kim JH, Kim HS, Shin MK, Kim JW, Kim HY. Serum gastrin levels in different stages of distal gastric carcinogenesis: Is there a role for serum gastrin in tumor growth? Turk J Gastroenterol. 2014;25(6):611-8

42. Jang HJ, Cho JW, Park B, Choi HC, Kim HS, Kim JH. The assessment of tumor response by measuring the single largest lesion per organ in metastatic tumors: a pooled analysis of previously reported data J Cancer. 2015;6(2):169-76.

43. Choi DR, Yoon SN, Kim HS, Kim JH, Kim KY, Kim BC, Choi YK, Kim JB, Han B, Song HH, Zang DY. A phase II study of capecitabine and oral leucovorin as a third-line chemotherapy in patients with metastatic colorectal cancer. Cancer Chemother Pharmacol. 2015;75(3):639-43.

44. Kim JH, Min SJ, Jang HJ, Cho JW, Kim SH, Kim HS. Comparison of RECIST 1.0 and RECIST 1.1 in Patients with Metastatic Cancer: A Pooled Analysis. J Cancer 2015;6(4):387-393.

45. Kim HS, Kim HY, Zang DY, Oh HS, Jeon JY, Cho JW, Park CK, Kim JH, Kim MJ, Ha HI, Kim JH, Han B, Song H, Kwon JH, Choi DR, Jung JY. Phase II study of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer. Cancer Chemother Pharmacol. 2015;75(4).

46. Kim JH. Chemotherapy for colorectal cancer in the elderly. World J Gastroenterol. 2015;21(17):5158-66.

47. Kim HY, Kim JS, Choi DR, Kim HS, Kwon JH, Jang GD, Kim JH, Jung JY, Song HH, Lee YK, Min SK, Hwang HS, Kim HJ, Zang DY, Kim HJ.The Clinical Utility of FDG PET-CT in Evaluation of Bone Marrow Involvement by Lymphoma. Cancer Res Treat. 2015 ;47(3):458-64.

48. Choi HC, Kim JH, Kim HS, Jung SG, Hwang SM, Ju SB, Yang I. Comparison of the RECIST 1.0 and RECIST 1.1 in Non-Small Cell Lung Cancer Treated with Cytotoxic Chemotherapy. J Cancer 2015;6:652-7.

49. Kim HS, Ryu MH, Zang DY, Ryoo BY, Yang DH, Cho JW, Lim MS, Kim MJ, Han B, Choi DR, Kim JH, Jung JY, Song H, Park CK, Kang YK. Phase II study of docetaxel, oxaliplatin, and S-1 therapy in patients with metastatic gastric cancer. Gastric Cancer. 2015

50. Jung JY, Ryu MH, Ryoo BY, Han B, Cho JW, Lim MS, Lim H, Kang HS, Kim MJ, Ha HI, Song H, Kim JH, Kim HS, Kang YK, Zang DY. Second-Line Irinotecan, Leucovorin, and 5-Fluorouracil for Gastric Cancer Patients after Failed Docetaxel and S-1. Gastroenterol Res Pract. 2016

51. Kim HS, Kim JH, Kim JW, Kim BC. Chemotherapy in Elderly Patients with Gastric Cancer. J Cancer. 2016;7(1):88-94.

52. Kim JH, Baek MJ, Ahn BK, Kim DD, Kim IY, Kim JS, Bae BN, Seo BG, Jung SH, Hong KH, Kim H, Park DG, Lee JH. Clinical Practice in the Use of Adjuvant Chemotherapy for Patients with Colon Cancer in South Korea: a Multi-Center, Prospective, Observational Study. J Cancer. 2016;7(2):136-43.

53. Kim JH. Comparison of the RECIST 1.0 and RECIST 1.1 in patients treated with targeted agents: a pooled analysis and review. Oncotarget. 2016.

54. Kim JH, Kim BJ, Kim HS, Clinicopathological impacts of high c-Met expression in head and neck squamous cell carcinoma: a meta-analysis and review. ONCOTARGET Vol. 8(68), pp. 113120~113128, 2017.

55. Kim JH, Kim BJ, Kim HS, Clinicopathological impacts of high c-Met expression in renal cell carcinoma: a meta-analysis and review. ONCOTARGET Vol. 8(43), pp. 75478~75487, 2017.

56. Kim JH, Kim HS, Kim BJ, MET inhibitors in advanced non-small-cell lung cancer: a meta-analysis and review. ONCOTARGET Vol. 8(43), pp. 75500~75508, 2017.

57. Kim JH, Kim BJ, Jang HJ, Lee J, Molecular targeted agents as second-line treatment for hepatocellular carcinoma: a meta-analysis and review. ONCOTARGET Vol. 8(60), pp. 102321~102327, 2017.

58. Kim BJ, Kim JH, Kim HS, Zang DY, Prognostic and predictive value of VHL gene alteration in renal cell carcinoma: a meta-analysis and review. ONCOTARGET Vol. 8(8), pp. 13979~13985, 2017.

59. Kim JH, Kim BJ, Kim HS, Lee J, Jang HJ, Prognostic value of c-Met overexpression in hepatocellular carcinoma: a meta-analysis and review. ONCOTARGET Vol. 8(52), pp. 90351~90357, 2017.

60. Kim JH, Kim HS, Kim HJ, Lee j, Jang HJ, Prognostic value of c-Met overexpression in pancreatic adenocarcinoma: a meta-analysis. ONCOTARGET Vol. 8(42), pp. 73098~73104, 2017.

61. Kim JH, Kim HS, Kim BJ, Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review. ONCOTARGET Vol. 8(29), pp. 48248~48252, 2017.

62. Kim JH, Kim HS, Kim BJ, Prognostic value of smoking status in non-small-cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis. ONCOTARGET Vol. 8(54), pp. 93149~93155, 2017.

63. Kim JH, Kim HS, Kim BJ, Jang HJ, Survival benefit of anti-angiogenic agents in patients with previously treated advanced gastric or gastroesophageal junction cancer: a meta-analysis. ONCOTARGET Vol. 8(57), pp. 97565~97570, 2017.

64. Kim BJ, Kim JH, Kim HS, Survival benefit of immune checkpoint inhibitors according to the histology in non-small-cell lung cancer: A meta-analysis and review. ONCOTARGET Vol. 8(31), pp. 51779~51785, 2017.

65. Jang HJ, Kim BJ, Kim JH, Kim HS, The addition of bevacizumab in the first-line treatment for metastatic colorectal cancer: an updated meta- analysis of randomized trials. ONCOTARGET Vol. 8(42), pp. 73009~73016, 2017.

66. Kim BJ, Jeong JH, Kim HS, Kim JH, The role of anti-EGFR agents in patients with locoregionally advanced head and neck cancer: a meta-analysis of randomized trials. ONCOTARGET Vol. 8(60), pp. 102371~102380, 2017.

67. Kim BJ, Kim JH, Jang HJ, Kim HS, The role of anti-EGFR agents in the first-line treatment of advanced esophago-gastric adenocarcinoma: a meta-analysis. ONCOTARGET Vol. 8(58), pp. 99033~99040, 2017.

68. Kim BJ, Jung JH, Kim JH, Kim HS, Jang HJ, The role of targeted agents in the adjuvant treatment of colon cancer: a meta-analysis of randomized phase III studies and review. ONCOTARGET Vol. 8(19), pp. 31112~31118, 2017.

69. Kim BJ, Jang HJ, Kim HS, KimJH, Current Status of Immune Checkpoint Inhibitors in Gastrointestinal Cancers. J CANCER Vol. 8(8), pp. 1460~1465, 2017.

70. Kim JH, Kim BJ, Jang HJ, Kim HS, Comparison of the RECIST and EORTC PET criteria in the tumor response assessment: a pooled analysis and review. CANCER CHEMOTH PHARM Vol. 80(4), pp. 729~735, 2017.

71. Kim BJ, Kim JH, Kim HS, Lee KY, Moderate to Severe Thrombocytopenia During Pregnancy: A Single Institutional Experience. INDIAN J HEMATOL BLO Vol. 33(4), pp. 581~585, 2017.

72. Kim HS, Kim JH, Jang HJ, Han B, Zang DY, Clinicopathologic Significance of VHL Gene Alteration in Clear-Cell Renal Cell Carcinoma: An Updated Meta-Analysis and Review. INT J MOL SCI Vol. 19(9), pp. E2529, 2018.

73. Kim JH, Kim HS, Kim BJ, Prognostic value of MET copy number gain in non-small-cell lung cancer: an updated meta-analysis. J CANCER Vol. 9(10), pp. 1836~1845, 2018.

74. Kim BJ, Kim HS, Jang HJ, Kim JH, Helicobacter pylori Eradication in Idiopathic Thrombocytopenic Purpura: A Meta-Analysis of Randomized Trials. GASTROENT RES PRACT Vol. 2018(), pp. 6090878, 2018.

75. Kim JH, Kim HS, Kim BJ, Han B, Choi DR, Kwon JH, Prognostic Impact of TTF-1 Expression in Non-Squamous Non-Small-Cell Lung Cancer: A Meta-Analysis. J CANCER Vol. (22), pp. 4279~4286, 2018.

76. Jang HJ, Kim HS, Kim JH, Lee J, The Effect of Statin Added to Systemic Anticancer Therapy: A Meta-Analysis of Randomized, Controlled Trials. J CLIN MED Vol. 7(10), pp. 1~13, 2018.

77. Kim JH, Jang HJ, Kim HS, Kim BJ, Park SH, Prognostic impact of high c-Met expression in ovarian cancer: a meta-analysis. J CANCER Vol. 9(19), pp. 3427~3434, 2018.

78. Oh SY, Shin SW, Koh SJ, Bae SB, Chang H, Kim JH, Kim HJ, Hong YS, Park KU, Park J, Lee KH, Lee NR, Lee JL, Jang JS, Hong DS, Lee SS, Baek SK, Choi DR, Chung J, Oh SC, Han HS, Yun HJ, Sym SJ, Yoon SY, Choi IS, Shim BY, Kang SY, Kim SR, Kim HJ, Multicenter, cross-sectional observational study of the impact of neuropathic pain on quality of life in cancer patients. SUPPORT CARE CANCER Vol. 25(12), pp. 3759~3767, 2017.

79. Yoo C, Han B, Kim HS, Kim KP, Kim D, Jeong JH, Lee JL, Kim TW, Kim JH, Choi DR, Ha HI, Seo J, Chang HM, Ryoo BY, Zang DY, Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-Line Treatment for Patients with Recurrent or Metastatic Biliary Tract Cancer. CANCER RES TREAT Vol. 50(4), pp. 1324~1330, 2018.

80. Kim HS, Ryu MH, Zang DY, Park SR, Han B, Kang WK, Rha SY, Jung M, Kim JS, Kang BW, Lee KH, Rho SY, Kim JH, Kim KC, Cho JW, Choi DR, Lim H, Kang HS, Soh JS, Kim MJ, Seo J, Kang YK, Phase II study of oxaliplatin, irinotecan and S-1 therapy in patients with advanced gastric cancer: the Korean Cancer Study Group ST14-11. GASTRIC CANCER Vol. 21(5), pp. 802~810, 2018.

81. Kim HS, Kim JH, Han B, Choi DR. Correlation of Thyroid Transcription Factor-1 Expression with EGFR Mutations in Non-Small-Cell Lung Cancer: A Meta-Analysis. Medicina (Kaunas). 2019, 7;55(2):41

82. Kim HS, Kim JH, Jang HJ, Han B, Zang DY. Pathological and Prognostic Impacts of FGFR2 Overexpression in Gastric Cancer: A Meta-Analysis. J Cancer. 2019;10(1):20-27.

83. Kim HD, Kim BJ, Kim HS, Kim JH. Comparison of the morphologic criteria (RECIST) and metabolic criteria (EORTC and PERCIST) in tumor response assessments: a pooled analysis. Korean J Intern Med. 2019;34(3):608-617.

84. Kim HS, Kim JH, Jang HJ. Pathologic and prognostic impacts of FGFR2 amplification in gastric cancer: a meta-analysis and systemic review. J Cancer. 2019;10(11):2560-2567


85. Kim HS, Kim JH, Jang HJ, Lee J. The addition of metformin to systemic anticancer therapy in advanced or metastatic cancers: a meta-analysis of randomized controlled trials. Int J Med Sci. 2020;17(16):2551-2560.

저서/저술

내용 숨기기
헨리에타 랙스의 불멸의 삶 (2012, 문학동네, 공역)
한평생의 지식 (2013, 민음사, 공저)
면역학 (2016, 공역, 라이프사이언스)
PP+ 면역학 (2020, 공편저, 라이프사이언스)

국제학회지 발표논문

내용 숨기기
1. Kim JH, Lee SH, Park J, Kim HY, Lee SI, Nam E, Park JO, Kim K, Jung CW, Im YH, Kang WK, Lee MH, Park K. Extrapulmonary small-cell carcinoma: a single-institution experience. Jpn J Clin Oncol 34:250-254, 2004.

2. Kim JH, Lee SH, Park J, Kim HY, Lee SI, Park JO, Kim K, Kim WS, Jung CW, Park YS, Im YH, Kang WK, Lee MH, Park K, Han JH, Ko YH. Primary pulmonary non-Hodgkin’s lymphoma. Jpn J Clin Oncol 34:510-514, 2004.

3. Lee SH, Kang WK, Park J, Kim HY, Kim JH, Lee SI, Park JO, Kim K, Jung CW, Park YS, Im YH, Lee MH, Park K. Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable gastric carcinoma. Br J Cancer 91:18-22, 2004.

4. Park J, Park BB, Kim JY, Lee SH, Lee SI, Kim HY, Kim JH, Park JO, Kim K, Jung CW, Park YS, Im YH, Kang WK, Lee MH, Park K. Gefitinib (ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small cell lung cancer. Clin Cancer Res 10:4383-4388, 2004.

5. Kim JH, Jung CW, Cho YH, Lee J, Lee SH, Kim HY, Park J, Park JO, Kim K, Kim WS, Park YS, Im YH, Kang WK, Park K. Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma. Oncol Report 13:859-864, 2005.

6. Oh SY, Ryoo BY, Kim WS, Kim K, Lee J, Kim HJ, Kwon JM, Lee HR, Ko YH, Oh SJ, Park KW, Kim HJ, Kwon HC, Nam E, Kim JH, Park YH, Lee SS, Kim HY, Park K. Nodal marginal zone B-cell lymphoma: analysis of 36 cases. Clinical presentation and treatment outcomes of nodal marginal zone B-cell lymphoma. Ann Hematol 85:781-786, 2006.

7. Lee J, Suh C, Park YH, Ko YH, Bang SM, Lee JH, Lee DH, Huh JR, Oh SY, Kwon HC, Kim HJ, Lee SI, Kim JH, Park J, Oh SJ, Kim K, Jung CW, Park K, Kim WS. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol 24:612-618, 2006.

8. Kim JH, Lee DH, Shin HC, Kwon JH, Jung JY, Kim HJ, Song HH, Lee KS, Zang DY, Ahn JS, Park YI, Lee JA. A phase study with gemcitabine and split-dose cisplatin in patients with non-small cell lung cancer. Lung Cancer 54:57-62, 2006.

9. Park BB, Ryoo BY, Lee JH, Kwon HC, Yang SH, Kang HJ, Oh SY, Ko YH, Huh JR, Lee SS, Nam E, Park KW, Kim JH, Kang JH, Bang SM, Park S, Kim K, Park K, Suh C, Kim WS. Clinical features and treatment outcomes of angioimmunoblastic T-cell lymphoma. Leuk Lymphoma 48:716-722, 2007.

10. Oh SY, Ryoo BY, Kim WS, Park YH, Kim K, Kim HJ, Kwon JM, Lee J, Ko YH, Ahn YC, Oh SJ, Lee SI, Kim HJ, Kwon HC, Bang SM, Kim JH, Park J, Lee SS, Kim HY, Park K. Nongastric marginal zone B-cell lymphoma: analysis of 247 cases. Am J Hematol 82:446-452, 2007.

11. Oh SY, Kwon HC, Kim WS, Hwang IG, Park YH, Kim K, Ko YH, Ryoo BY, Kang HJ, Nam E, Lee JH, Kim JH, Kim HJ. Intestinal marginal zone B-cell lymphoma of MALT type: clinical manifestation and outcome of rare disease. Eur J Haematol 79:287-291, 2007.

12. Park BB, Kim JG, Sohn SK, Kang HJ, Kang JH, Lee SS, HS Eom, Kwon HC, Oh SY, Shin HJ, Suh C, Kim JH, Kim HY, Kim K, Ryoo BY, Kim WS. Consideration of aggressive therapeutic strategies for primary testicular lymphoma. Am J Hematol 82:840-845, 2007.

13. Oh SY, Kwon HC, Kim WS, Park YH, Kim K, Kim HJ, Kwon JM, Lee J, Ko YH, Ahn YC, Oh SJ, Lee SI, Bang SM, Kim JH, Park J, Ryoo BY, Lee SS, Kim HY, Park K, Kim HJ. Nongastric marginal zone B-cell lymphoma: A prognostic model from a retrospective multicenter study. Cancer Lett 258: 90-97, 2007

14. Kim JH, Lee Y, Bae YS, Kim WS, Kim K, Im HY, Kang WK, Park K, Choi HY, Lee HM, Baek SY, Lee H, Doh H, Kim BM, Kim CY, Jeon CJ, Jung CW. Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma. Clin Immunol 2007;125:257-267.

15. Kim JH, Kim HS, Sung CW, Kim KJ, Kim CH, Lee KY. Docetaxel, gemcitabine, and cisplatin administered for non-small cell lung cancer during the first and second trimester of an unrecognized pregnancy. Lung Cancer 59:270-273, 2008

16. Jang HJ, Kim JH, Song HH, Woo KH, Kim M, Kae SH, Lee J, Cho JW, Kang JH, Lee SI, Gong SJ, Lee JA, Zang DY. Clinical Outcomes of Patients with Liver Cirrhosis Who Underwent Curative Surgery for Gastric Cancer: A Retrospective Multi-center Study. Dig Dis Sci 53:399-404, 2008.

17. Zang DY, Yang DH, Lee HW, Hwang SW, Song HH, Jung JY, Kwon JH, Kim HJ, Kim JH, Park SR, Kim MJ, Jang KM, Park CK, Kim JH, Lee BH. Phase I/II trial with docetaxel and S-1 for patients with advanced or recurrent gastric cancer with consideration to age. Cancer Chemother Pharmacol 63:509-516, 2009.

18. Kim JH, Kin HS et al. Bilateral subdural hematoma as a possible adverse events of gefitinib in a patient with non-small cell lung cancer. Lung Cancer, 64;121-3, 2009.

19. Jung JY, Kwon JH, Kim JH, Song HH, Kim I, Lee KS, Kim HJ, Zang DY, Ahn JS, Lee JA, Park YI. Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer. Oncol Rep 21:523-529, 2009.

20. Zang DY, Lee BH, Park HC, Song HH, Kim HJ, Jung JY, Kim JH, Kim HY, Kwon JH, Hwang SW, Park SR, Park CH, Kim KO, Kim MJ, Jang KM. Phase II study with oxaliplatin and S-1 for patients with metastatic colorectal cancer. Ann Oncol 20;892-896, 2009.

21. Zang DY, Yang DH, Kim MJ, Jang KM, Hwang SW, Yoo KS, Han T, Kim HY, Kim HJ, Kwon JH, Song HH, Park S, Jung JY, Kim HS, Kim JH. Dose-finding study of docetaxel, oxaliplatin, and S-1 for patients with advanced gastric cancer. Cancer Chemother Pharmacol. 64:877-83, 2009.

22. Kim JH, Kim HS, Kwon JH, Park S, Kim HY, Jung JY, Kim HJ, Song HH, Lee GW, Lee SI, Gong SJ, Lee JA, Kim KJ, Zang DY. Systemic chemotherapy after cranial irradiation in patients with brain metastases from non-small cell lung cancer: a retrospective study. Lung Cancer
63;405-409, 2009.

23. Kim HS, Lee GW, Kim JH, Kim HY, Kwon JH, Song HH, Kim HJ, Jung JY, Jang G, Choi DR, Park SM, Shin TR, Lee HS, Zang DY. A phase II study of pemetrexed and carboplatin as a salvage therapy for platinum-pretreated patients with non-small cell lung cancer. Lung Cancer. 70:71-6, 2010.

24. Kwon JH, Kim JH, Lee JA, Shin HC, Kim HJ, Song HH, Jung JY, Kim HY, Choi DR, Kim HS, Park YI, Zang DY. Phase II study with fractionated schedule of docetaxel and cisplatin in patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 66:889-97, 2010.

25. Kim JH, Kim M, Sung CW, Kim HS, Jang HJ, Shin YC, Jung JY. High-dose fentanyl patch for cancer pain of a patient with cholangiocarcinoma. Korean J Intern Med. 25:337-40, 2010.

26. Kim HS, Park YH, Lee J, Ahn JS, Kim J, Shim YM, Kim JH, Park K, Han J, Ahn MJ. Clinical impact of phosphorylated signal transducer and activator of transcription 3, epidermal growth factor receptor, p53, and vascular endothelial growth factor receptor 1 expression in resected adenocarcinoma of lung by using tissue microarray. Cancer 116:676-85, 2010.

27. Kim JH, Kim HS, Choi DR, Jang G, Kwon JH, Kim HY, Jung JY, Kim HJ, Song HH, Shin YH, Jung SY, Kim BC, Zang DY. A phase II study of mitomycin-C and S-1 as third-line chemotherapy in patients with advanced colorectal cancer. Oncol Lett. 2:1253-1256, 2011

28. Kim HJ, Moh IH, Yoo H, Son S, Jung DH, Lee HG, Han DH, Park JH, Kim HS, Kim JH. Ethylenediaminetetraacetic acid-dependent pseudothrombocytopenia associated with neuroendocrine carcinoma: A case report. Oncol Lett. 4:86-88, 2012.

29. Kim HS, Kim JH, Kim HJ, Jang HJ, Kim JB, Kim JW, Jung SY, Kim BC, Yang DH, Park S, Kim KJ, Lee SI, Zang DY. Oxaliplatin, 5-fluorouracil and leucovorin (modified FOLFOX-6) as first-line chemotherapy for advanced gastric cancer patients with poor performance status. Oncol Lett. 3:425-428, 2012.

30. Kim JH, Kim HS, Han AR, Moh IH, Chung DC, Choi DR, Jang HJ, Kim JB, Yang DH, Lee SI, Zang DY. Irinotecan, leucovorin and 5-fluorouracil (modified FOLFIRI) as salvage chemotherapy for frail or elderly patients with advanced gastric cancer. Oncol Lett. 4:751-754, 2012.

31. Kwon JH, Oh SY, Chisholm G, Lee JA, Lee JJ, Park KW, Nam SH, Song HH, Lee K, Zang DY, Kim HY, Choi DR, Kim HJ, Kim JH, Jung JY, Jang G, Kim HS, Won JY, Bruera E. Predictors of high score patient-reported barriers to controlling cancer pain: a preliminary report. Support Care Cancer 21:1175-1183, 2013.

32. Kim HS, Kim JH, Kim B, Choi HC, Kwon JH, Choi DR. Phase II study of weekly carboplatin and irinotecan as first-line chemotherapy for patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol 71:1591-1597, 2013

33. Song H, Han B, Park CK, Kim JH, Jeon JY, Kim IG, Kim HJ, Jung JY, Kim JH, Kwon JH, Jang G, Kim HY, Kim HS, Choi DR, Zang DY. Phase II trial of gemcitabine and S-1 for patients with advanced pancreatic cancer. Cancer Chemother Pharmacol. 2013

34. Jang G, Song HH, Park KU, Kim HS, Choi DR, Kwon JH, Kim HY, Han B, Kim JH, Jung JY, Kim HJ, Zang DY. A Phase II Study to Evaluate the Efficacy of Ramosetron, Aprepitant, and Dexamethasone in Preventing Cisplatin-Induced Nausea and Vomiting in Chemotherapy-Naïve Cancer Patients. Cancer Res Treat 45(3):172-7, 2013

35. Jang GS, Kim MJ, Ha HI, Kim JH, Kim HS, Ju SB, Zang DY. Comparison of RECIST version 1.0 and 1.1 in assessment of tumor response by computed tomography in advanced gastric cancer. Chin J Cancer Res 25(6):689-94, 2013

36. Jang HJ, Kim BC, Kim HS, Kim JH, Song HH, Kim JB, Park JJ, Yoon SN, Woo JY, Zang DY. Comparison of RECIST 1.0 and RECIST 1.1 on Computed Tomography in Patients with Metastatic Colorectal Cancer. Oncology 25;86(2):117-121, 2014.

37. Kim HS, Kim JH, Yang I. Tumor response assessment by measuring the single largest lesion per organ in patients with advanced non-small cell lung cancer. Lung Cancer, 85: 385-389, 2014.

38. Kim HS, Kim JH. Ideal number of target lesions per organ to measure in metastatic colorectal cancer. Oncol Lett, 2014;8:1896-1900.
39. Kim HS, Kim JW, Kim JH, Choi DR, Kim M-J, Han AR, et al. The single-lesion measurement for assessing tumor response in patients advanced gastric cancer. Oncology. 2015;88:69-75.

40. Kang JH, Oh SY, Song SY, Lee HY, Kim JH, Lee KE, Lee HR, Hwang IG, Park SH, Kim WS, Park YS, Park K. The efficacy of low-dose transdermal fentanyl in opioid-naïve cancer patients with moderate-to-severe pain. Korean J Intern Med. 2015;30(1):88-95.

41. Kim BC, Jung SW, Kim JB, Han AR, Jang SI, Park SH, Lee MS, Yoon JH, Baik GH, Jang HJ, Kim JH, Kim HS, Shin MK, Kim JW, Kim HY. Serum gastrin levels in different stages of distal gastric carcinogenesis: Is there a role for serum gastrin in tumor growth? Turk J Gastroenterol. 2014;25(6):611-8

42. Jang HJ, Cho JW, Park B, Choi HC, Kim HS, Kim JH. The assessment of tumor response by measuring the single largest lesion per organ in metastatic tumors: a pooled analysis of previously reported data J Cancer. 2015;6(2):169-76.

43. Choi DR, Yoon SN, Kim HS, Kim JH, Kim KY, Kim BC, Choi YK, Kim JB, Han B, Song HH, Zang DY. A phase II study of capecitabine and oral leucovorin as a third-line chemotherapy in patients with metastatic colorectal cancer. Cancer Chemother Pharmacol. 2015;75(3):639-43.

44. Kim JH, Min SJ, Jang HJ, Cho JW, Kim SH, Kim HS. Comparison of RECIST 1.0 and RECIST 1.1 in Patients with Metastatic Cancer: A Pooled Analysis. J Cancer 2015;6(4):387-393.

45. Kim HS, Kim HY, Zang DY, Oh HS, Jeon JY, Cho JW, Park CK, Kim JH, Kim MJ, Ha HI, Kim JH, Han B, Song H, Kwon JH, Choi DR, Jung JY. Phase II study of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer. Cancer Chemother Pharmacol. 2015;75(4).

46. Kim JH. Chemotherapy for colorectal cancer in the elderly. World J Gastroenterol. 2015;21(17):5158-66.

47. Kim HY, Kim JS, Choi DR, Kim HS, Kwon JH, Jang GD, Kim JH, Jung JY, Song HH, Lee YK, Min SK, Hwang HS, Kim HJ, Zang DY, Kim HJ.The Clinical Utility of FDG PET-CT in Evaluation of Bone Marrow Involvement by Lymphoma. Cancer Res Treat. 2015 ;47(3):458-64.

48. Choi HC, Kim JH, Kim HS, Jung SG, Hwang SM, Ju SB, Yang I. Comparison of the RECIST 1.0 and RECIST 1.1 in Non-Small Cell Lung Cancer Treated with Cytotoxic Chemotherapy. J Cancer 2015;6:652-7.

49. Kim HS, Ryu MH, Zang DY, Ryoo BY, Yang DH, Cho JW, Lim MS, Kim MJ, Han B, Choi DR, Kim JH, Jung JY, Song H, Park CK, Kang YK. Phase II study of docetaxel, oxaliplatin, and S-1 therapy in patients with metastatic gastric cancer. Gastric Cancer. 2015

50. Jung JY, Ryu MH, Ryoo BY, Han B, Cho JW, Lim MS, Lim H, Kang HS, Kim MJ, Ha HI, Song H, Kim JH, Kim HS, Kang YK, Zang DY. Second-Line Irinotecan, Leucovorin, and 5-Fluorouracil for Gastric Cancer Patients after Failed Docetaxel and S-1. Gastroenterol Res Pract. 2016

51. Kim HS, Kim JH, Kim JW, Kim BC. Chemotherapy in Elderly Patients with Gastric Cancer. J Cancer. 2016;7(1):88-94.

52. Kim JH, Baek MJ, Ahn BK, Kim DD, Kim IY, Kim JS, Bae BN, Seo BG, Jung SH, Hong KH, Kim H, Park DG, Lee JH. Clinical Practice in the Use of Adjuvant Chemotherapy for Patients with Colon Cancer in South Korea: a Multi-Center, Prospective, Observational Study. J Cancer. 2016;7(2):136-43.

53. Kim JH. Comparison of the RECIST 1.0 and RECIST 1.1 in patients treated with targeted agents: a pooled analysis and review. Oncotarget. 2016.

54. Kim JH, Kim BJ, Kim HS, Clinicopathological impacts of high c-Met expression in head and neck squamous cell carcinoma: a meta-analysis and review. ONCOTARGET Vol. 8(68), pp. 113120~113128, 2017.

55. Kim JH, Kim BJ, Kim HS, Clinicopathological impacts of high c-Met expression in renal cell carcinoma: a meta-analysis and review. ONCOTARGET Vol. 8(43), pp. 75478~75487, 2017.

56. Kim JH, Kim HS, Kim BJ, MET inhibitors in advanced non-small-cell lung cancer: a meta-analysis and review. ONCOTARGET Vol. 8(43), pp. 75500~75508, 2017.

57. Kim JH, Kim BJ, Jang HJ, Lee J, Molecular targeted agents as second-line treatment for hepatocellular carcinoma: a meta-analysis and review. ONCOTARGET Vol. 8(60), pp. 102321~102327, 2017.

58. Kim BJ, Kim JH, Kim HS, Zang DY, Prognostic and predictive value of VHL gene alteration in renal cell carcinoma: a meta-analysis and review. ONCOTARGET Vol. 8(8), pp. 13979~13985, 2017.

59. Kim JH, Kim BJ, Kim HS, Lee J, Jang HJ, Prognostic value of c-Met overexpression in hepatocellular carcinoma: a meta-analysis and review. ONCOTARGET Vol. 8(52), pp. 90351~90357, 2017.

60. Kim JH, Kim HS, Kim HJ, Lee j, Jang HJ, Prognostic value of c-Met overexpression in pancreatic adenocarcinoma: a meta-analysis. ONCOTARGET Vol. 8(42), pp. 73098~73104, 2017.

61. Kim JH, Kim HS, Kim BJ, Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review. ONCOTARGET Vol. 8(29), pp. 48248~48252, 2017.

62. Kim JH, Kim HS, Kim BJ, Prognostic value of smoking status in non-small-cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis. ONCOTARGET Vol. 8(54), pp. 93149~93155, 2017.

63. Kim JH, Kim HS, Kim BJ, Jang HJ, Survival benefit of anti-angiogenic agents in patients with previously treated advanced gastric or gastroesophageal junction cancer: a meta-analysis. ONCOTARGET Vol. 8(57), pp. 97565~97570, 2017.

64. Kim BJ, Kim JH, Kim HS, Survival benefit of immune checkpoint inhibitors according to the histology in non-small-cell lung cancer: A meta-analysis and review. ONCOTARGET Vol. 8(31), pp. 51779~51785, 2017.

65. Jang HJ, Kim BJ, Kim JH, Kim HS, The addition of bevacizumab in the first-line treatment for metastatic colorectal cancer: an updated meta- analysis of randomized trials. ONCOTARGET Vol. 8(42), pp. 73009~73016, 2017.

66. Kim BJ, Jeong JH, Kim HS, Kim JH, The role of anti-EGFR agents in patients with locoregionally advanced head and neck cancer: a meta-analysis of randomized trials. ONCOTARGET Vol. 8(60), pp. 102371~102380, 2017.

67. Kim BJ, Kim JH, Jang HJ, Kim HS, The role of anti-EGFR agents in the first-line treatment of advanced esophago-gastric adenocarcinoma: a meta-analysis. ONCOTARGET Vol. 8(58), pp. 99033~99040, 2017.

68. Kim BJ, Jung JH, Kim JH, Kim HS, Jang HJ, The role of targeted agents in the adjuvant treatment of colon cancer: a meta-analysis of randomized phase III studies and review. ONCOTARGET Vol. 8(19), pp. 31112~31118, 2017.

69. Kim BJ, Jang HJ, Kim HS, KimJH, Current Status of Immune Checkpoint Inhibitors in Gastrointestinal Cancers. J CANCER Vol. 8(8), pp. 1460~1465, 2017.

70. Kim JH, Kim BJ, Jang HJ, Kim HS, Comparison of the RECIST and EORTC PET criteria in the tumor response assessment: a pooled analysis and review. CANCER CHEMOTH PHARM Vol. 80(4), pp. 729~735, 2017.

71. Kim BJ, Kim JH, Kim HS, Lee KY, Moderate to Severe Thrombocytopenia During Pregnancy: A Single Institutional Experience. INDIAN J HEMATOL BLO Vol. 33(4), pp. 581~585, 2017.

72. Kim HS, Kim JH, Jang HJ, Han B, Zang DY, Clinicopathologic Significance of VHL Gene Alteration in Clear-Cell Renal Cell Carcinoma: An Updated Meta-Analysis and Review. INT J MOL SCI Vol. 19(9), pp. E2529, 2018.

73. Kim JH, Kim HS, Kim BJ, Prognostic value of MET copy number gain in non-small-cell lung cancer: an updated meta-analysis. J CANCER Vol. 9(10), pp. 1836~1845, 2018.

74. Kim BJ, Kim HS, Jang HJ, Kim JH, Helicobacter pylori Eradication in Idiopathic Thrombocytopenic Purpura: A Meta-Analysis of Randomized Trials. GASTROENT RES PRACT Vol. 2018(), pp. 6090878, 2018.

75. Kim JH, Kim HS, Kim BJ, Han B, Choi DR, Kwon JH, Prognostic Impact of TTF-1 Expression in Non-Squamous Non-Small-Cell Lung Cancer: A Meta-Analysis. J CANCER Vol. (22), pp. 4279~4286, 2018.

76. Jang HJ, Kim HS, Kim JH, Lee J, The Effect of Statin Added to Systemic Anticancer Therapy: A Meta-Analysis of Randomized, Controlled Trials. J CLIN MED Vol. 7(10), pp. 1~13, 2018.

77. Kim JH, Jang HJ, Kim HS, Kim BJ, Park SH, Prognostic impact of high c-Met expression in ovarian cancer: a meta-analysis. J CANCER Vol. 9(19), pp. 3427~3434, 2018.

78. Oh SY, Shin SW, Koh SJ, Bae SB, Chang H, Kim JH, Kim HJ, Hong YS, Park KU, Park J, Lee KH, Lee NR, Lee JL, Jang JS, Hong DS, Lee SS, Baek SK, Choi DR, Chung J, Oh SC, Han HS, Yun HJ, Sym SJ, Yoon SY, Choi IS, Shim BY, Kang SY, Kim SR, Kim HJ, Multicenter, cross-sectional observational study of the impact of neuropathic pain on quality of life in cancer patients. SUPPORT CARE CANCER Vol. 25(12), pp. 3759~3767, 2017.

79. Yoo C, Han B, Kim HS, Kim KP, Kim D, Jeong JH, Lee JL, Kim TW, Kim JH, Choi DR, Ha HI, Seo J, Chang HM, Ryoo BY, Zang DY, Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-Line Treatment for Patients with Recurrent or Metastatic Biliary Tract Cancer. CANCER RES TREAT Vol. 50(4), pp. 1324~1330, 2018.

80. Kim HS, Ryu MH, Zang DY, Park SR, Han B, Kang WK, Rha SY, Jung M, Kim JS, Kang BW, Lee KH, Rho SY, Kim JH, Kim KC, Cho JW, Choi DR, Lim H, Kang HS, Soh JS, Kim MJ, Seo J, Kang YK, Phase II study of oxaliplatin, irinotecan and S-1 therapy in patients with advanced gastric cancer: the Korean Cancer Study Group ST14-11. GASTRIC CANCER Vol. 21(5), pp. 802~810, 2018.

81. Kim HS, Kim JH, Han B, Choi DR. Correlation of Thyroid Transcription Factor-1 Expression with EGFR Mutations in Non-Small-Cell Lung Cancer: A Meta-Analysis. Medicina (Kaunas). 2019, 7;55(2):41

82. Kim HS, Kim JH, Jang HJ, Han B, Zang DY. Pathological and Prognostic Impacts of FGFR2 Overexpression in Gastric Cancer: A Meta-Analysis. J Cancer. 2019;10(1):20-27.

83. Kim HD, Kim BJ, Kim HS, Kim JH. Comparison of the morphologic criteria (RECIST) and metabolic criteria (EORTC and PERCIST) in tumor response assessments: a pooled analysis. Korean J Intern Med. 2019;34(3):608-617.

84. Kim HS, Kim JH, Jang HJ. Pathologic and prognostic impacts of FGFR2 amplification in gastric cancer: a meta-analysis and systemic review. J Cancer. 2019;10(11):2560-2567


85. Kim HS, Kim JH, Jang HJ, Lee J. The addition of metformin to systemic anticancer therapy in advanced or metastatic cancers: a meta-analysis of randomized controlled trials. Int J Med Sci. 2020;17(16):2551-2560.

저서/저술

내용 숨기기
헨리에타 랙스의 불멸의 삶 (2012, 문학동네, 공역)
한평생의 지식 (2013, 민음사, 공저)
면역학 (2016, 공역, 라이프사이언스)
PP+ 면역학 (2020, 공편저, 라이프사이언스)